JENNER TECHNOLOGIES has a total of 19 patent applications. Its first patent ever was published in 1992. It filed its patents most often in Canada, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, machines and biotechnology are NABI BIOPHARMACEUTICALS, AMBRYX BIOTECHNOLOGY INC and MOLECULAR RX INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 4 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Australia | 3 | |
#5 | Japan | 2 | |
#6 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Machines | |
#3 | Biotechnology | |
#4 | Measurement | |
#5 | Micro-structure and nano-technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Unspecified technologies | |
#3 | Peptides | |
#4 | Therapeutic chemical compounds | |
#5 | Analysing materials | |
#6 | Nanostructure applications |
# | Name | Total Patents |
---|---|---|
#1 | Spitler Lynn E | 14 |
#2 | Alving Carl R | 4 |
#3 | Maida Anthony E Iii | 4 |
#4 | Muderhwa Jean M | 4 |
#5 | Maida Iii Anthony E | 2 |
Publication | Filing date | Title |
---|---|---|
WO9504548A1 | Prostatic cancer vaccine | |
CA2139743A1 | Stimulation of an antitumor t-cell response using anti-idiotypic antibodies | |
CA2123696A1 | Antitumor vaccines |